Tech Company Financing Transactions
Aardvark Therapeutics Funding Round
Aardvark Therapeutics, operating out of San Diego, scored $29 million from Sorrento Therapeutics, BNH Investment and Foundation for Prader-Willi Research.
Transaction Overview
Company Name
Announced On
8/9/2021
Transaction Type
Venture Equity
Amount
$29,000,000
Round
Series B
Investors
Proceeds Purpose
The funds raised will be deployed to: complete three Phase 2 clinical trials of the company's lead compound, ARD-101, a first-in-class small molecule TAS2R (bitter taste receptor) pan-agonist; and to advance several potential additional formulations for major indications. ARD-101 demonstrated safety in Phase 1 human trials. Further, ARD-101 has been shown to convey beneficial effects in animal models of obesity as well as hyperphagia, diabetes, hyperlipidemia, and inflammation.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
12707 High Bluff Dr. 200
San Diego, CA 92130-2035
USA
San Diego, CA 92130-2035
USA
Phone
Website
Email Address
Overview
Aardvark Therapeutics specializes in small molecule therapeutics for obesity and rare genetic metabolic disorders. Aardvark Therapeutics was founded by Tien Lee in 2017.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Tien Lee
Chief Financial Officer
Nelson Sun
Chief Marketing Officer
Andreas Niethammer
Chief Scientific Officer
Zhenhuan Zheng
VP - Operations
Anjuli Timmer
Browse more venture capital transactions:
Prev: 8/9/2021: Carputty venture capital transaction
Next: 8/9/2021: SentiLink venture capital transaction
Share this article
Where The Data Comes From
Our team works diligently to report on every notable VC transaction. VC investment data records reported here are sourced from publicly available VC deal announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs